Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Oxyaapa: A Picolinate-Based Ligand with Five Oxygen Donors that Strongly Chelates Lanthanides.

Hu A, Keresztes I, MacMillan SN, Yang Y, Ding E, Zipfel WR, DiStasio RA Jr, Babich JW, Wilson JJ.

Inorg Chem. 2020 Mar 27. doi: 10.1021/acs.inorgchem.0c00372. [Epub ahead of print]

PMID:
32216281
2.

Otto: a 4.04 GBq (109 mCi) 68Ge/68Ga generator, first of its kind - extended quality control and performance evaluation in the clinical production of [68Ga]Ga-PSMA-11.

Waterhouse NN, Amor-Coarasa A, Nikolopoulou A, Babich JW.

EJNMMI Radiopharm Chem. 2020 Feb 3;5(1):5. doi: 10.1186/s41181-019-0087-y.

3.

3D-printed automation for optimized PET radiochemistry.

Amor-Coarasa A, Kelly JM, Babich JW.

Sci Adv. 2019 Sep 13;5(9):eaax4762. doi: 10.1126/sciadv.aax4762. eCollection 2019 Sep.

4.

Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO.

Bhupathiraju NVSDK, Younes A, Cao M, Ali J, Cicek HT, Tully KM, Ponnala S, Babich JW, Deri MA, Lewis JS, Francesconi LC, Drain CM.

Org Biomol Chem. 2019 Jul 17;17(28):6866-6871. doi: 10.1039/c9ob01068h.

PMID:
31268109
5.

[18F]Fluoroethyltriazolyl Monocyclam Derivatives as Imaging Probes for the Chemokine Receptor CXCR4.

Amor-Coarasa A, Kelly JM, Singh PK, Ponnala S, Nikolopoulou A, Williams C Jr, Vedvyas Y, Jin MM, Warren JD, Babich JW.

Molecules. 2019 Apr 24;24(8). pii: E1612. doi: 10.3390/molecules24081612.

6.

Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.

Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, DiMagno SG, Babich JW.

J Nucl Med. 2019 May;60(5):656-663. doi: 10.2967/jnumed.118.221150. Epub 2018 Dec 14.

PMID:
30552199
7.

A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model.

Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, Thiele NA, Schlyer D, Wilson JJ, DiMagno SG, Babich JW.

J Nucl Med. 2019 May;60(5):649-655. doi: 10.2967/jnumed.118.219592. Epub 2018 Nov 9.

PMID:
30413660
8.

66Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?

Amor-Coarasa A, Kelly JM, Ponnala S, Nikolopoulou A, Williams C Jr, Babich JW.

Molecules. 2018 Oct 9;23(10). pii: E2575. doi: 10.3390/molecules23102575.

9.

Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.

Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, Schlyer D, Zhao Y, Kim D, Babich JW.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1841-1851. doi: 10.1007/s00259-018-4004-5. Epub 2018 Apr 6.

PMID:
29623376
10.

[18F]RPS-544: A PET tracer for imaging the chemokine receptor CXCR4.

Amor-Coarasa A, Kelly J, Ponnala S, Vedvyas Y, Nikolopoulou A, Williams C Jr, Jin MM, David Warren J, Babich JW.

Nucl Med Biol. 2018 May;60:37-44. doi: 10.1016/j.nucmedbio.2018.01.004. Epub 2018 Jan 31.

PMID:
29544122
11.

Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.

Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Sep;59(9):1373-1379. doi: 10.2967/jnumed.117.200220. Epub 2018 Jan 25.

12.

Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68Ga3+, 111In3+, 177Lu3+ and 225Ac3.

Kelly JM, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C Jr, Vallabhajosula S, Babich JW.

Nucl Med Biol. 2017 Dec;55:38-46. doi: 10.1016/j.nucmedbio.2017.10.001. Epub 2017 Oct 3.

PMID:
29055836
13.

An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.

Thiele NA, Brown V, Kelly JM, Amor-Coarasa A, Jermilova U, MacMillan SN, Nikolopoulou A, Ponnala S, Ramogida CF, Robertson AKH, Rodríguez-Rodríguez C, Schaffer P, Williams C Jr, Babich JW, Radchenko V, Wilson JJ.

Angew Chem Int Ed Engl. 2017 Nov 13;56(46):14712-14717. doi: 10.1002/anie.201709532. Epub 2017 Oct 16.

PMID:
28963750
14.

Continuation of comprehensive quality control of the itG 68Ge/68Ga generator and production of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for clinical research studies.

Amor-Coarasa A, Kelly JM, Gruca M, Nikolopoulou A, Vallabhajosula S, Babich JW.

Nucl Med Biol. 2017 Oct;53:37-39. doi: 10.1016/j.nucmedbio.2017.07.006. Epub 2017 Jul 14.

PMID:
28803001
15.

Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.

Kelly JM, Amor-Coarasa A, Nikolopoulou A, Wüstemann T, Barelli P, Kim D, Williams C Jr, Zheng X, Bi C, Hu B, Warren JD, Hage DS, DiMagno SG, Babich JW.

J Nucl Med. 2017 Sep;58(9):1442-1449. doi: 10.2967/jnumed.116.188722. Epub 2017 Apr 27.

16.

Radioiodinated Capsids Facilitate In Vivo Non-Invasive Tracking of Adeno-Associated Gene Transfer Vectors.

Kothari P, De BP, He B, Chen A, Chiuchiolo MJ, Kim D, Nikolopoulou A, Amor-Coarasa A, Dyke JP, Voss HU, Kaminsky SM, Foley CP, Vallabhajosula S, Hu B, DiMagno SG, Sondhi D, Crystal RG, Babich JW, Ballon D.

Sci Rep. 2017 Jan 6;7:39594. doi: 10.1038/srep39594.

17.

Differential in radiosensitizing potency of enantiomers of the fatty acid synthase inhibitor C75.

Rae C, Babich JW, Mairs RJ.

Chirality. 2017 Jan;29(1):10-13. doi: 10.1002/chir.22668. Epub 2016 Nov 30.

18.

Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.

Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C Jr, Ponnala S, Babich JW.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):647-661. doi: 10.1007/s00259-016-3556-5. Epub 2016 Nov 15.

19.

The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.

Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U.

J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S. Review.

20.

Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.

Tesson M, Rae C, Nixon C, Babich JW, Mairs RJ.

J Pharm Pharmacol. 2016 Jul;68(7):912-21. doi: 10.1111/jphp.12558. Epub 2016 May 3.

21.

Comprehensive Quality Control of the ITG 68Ge/68Ga Generator and Synthesis of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for Clinical Imaging.

Amor-Coarasa A, Schoendorf M, Meckel M, Vallabhajosula S, Babich JW.

J Nucl Med. 2016 Sep;57(9):1402-5. doi: 10.2967/jnumed.115.171249. Epub 2016 Apr 21.

22.

New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.

Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M.

Clin Cancer Res. 2016 Jan 1;22(1):9-15. doi: 10.1158/1078-0432.CCR-15-0820. Review.

23.

Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy.

Rae C, Haberkorn U, Babich JW, Mairs RJ.

Radiat Res. 2015 Nov;184(5):482-93. doi: 10.1667/RR14173.1. Epub 2015 Oct 20.

PMID:
26484401
24.

Synthesis of [11C]palmitic acid for PET imaging using a single molecular sieve 13X cartridge for reagent trapping, radiolabeling and selective purification.

Amor-Coarasa A, Kelly JM, Babich JW.

Nucl Med Biol. 2015 Aug;42(8):685-90. doi: 10.1016/j.nucmedbio.2015.03.008. Epub 2015 Apr 9.

PMID:
25934348
25.

PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer.

Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, Kopka K, Babich JW, Haberkorn U.

J Nucl Med. 2015 Feb;56(2):293-8. doi: 10.2967/jnumed.114.147181. Epub 2015 Jan 22.

26.

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.

Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ.

J Nucl Med. 2014 Nov;55(11):1791-8. doi: 10.2967/jnumed.114.140426. Epub 2014 Oct 23.

27.

Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane.

Chin BB, Kronauge JF, Femia FJ, Chen J, Maresca KP, Hillier S, Petry NA, James OG, Oldan JD, Armor T, Stubbs JB, Stabin MG, Babich JW.

J Nucl Med. 2014 May;55(5):765-71. doi: 10.2967/jnumed.113.124057. Epub 2014 Mar 13.

28.

Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.

Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92. doi: 10.1007/s00259-014-2713-y. Epub 2014 Feb 28.

29.

Single amino acid chelate complexes of the M(CO)3 (+) core for correlating fluorescence and radioimaging studies (M = (99m) Tc or Re).

Coogan MP, Doyle RP, Valliant JF, Babich JW, Zubieta J.

J Labelled Comp Radiopharm. 2014 Apr;57(4):255-61. doi: 10.1002/jlcr.3164. Epub 2014 Jan 7. Review.

PMID:
24395431
30.

Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52.

Mier W, Kratochwil C, Hassel JC, Giesel FL, Beijer B, Babich JW, Friebe M, Eisenhut M, Enk A, Haberkorn U.

J Nucl Med. 2014 Jan;55(1):9-14. doi: 10.2967/jnumed.112.112789. Epub 2013 Nov 25.

31.

Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.

Rae C, Tesson M, Babich JW, Boyd M, Mairs RJ.

EJNMMI Res. 2013 Nov 13;3(1):73. doi: 10.1186/2191-219X-3-73.

32.

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.

Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.

J Nucl Med. 2013 Aug;54(8):1369-76. doi: 10.2967/jnumed.112.116624. Epub 2013 Jun 3.

33.

The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells.

Rae C, Tesson M, Babich JW, Boyd M, Sorensen A, Mairs RJ.

J Nucl Med. 2013 Jun;54(6):953-60. doi: 10.2967/jnumed.112.113324. Epub 2013 Apr 24.

34.

Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) promoter.

McCluskey AG, Mairs RJ, Sorensen A, Robson T, McCarthy HO, Pimlott SL, Babich JW, Champion S, Boyd M.

Radiat Res. 2013 Mar;179(3):282-92. doi: 10.1667/RR3030.1. Epub 2013 Jan 21.

PMID:
23336184
35.

Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates.

Lu G, Maresca KP, Hillier SM, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1557-63. doi: 10.1016/j.bmcl.2012.09.014. Epub 2012 Sep 13.

PMID:
23333070
36.

First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer.

Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, Armor T, Stubbs JB, Maresca KP, Stabin MG, Joyal JL, Eckelman WC, Babich JW.

J Nucl Med. 2013 Mar;54(3):380-7. doi: 10.2967/jnumed.112.111203. Epub 2013 Jan 9.

37.

Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.

Lu G, Hillier SM, Maresca KP, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.

J Med Chem. 2013 Jan 24;56(2):510-20. doi: 10.1021/jm3015348. Epub 2013 Jan 8.

PMID:
23234246
38.

Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.

McCluskey AG, Mairs RJ, Tesson M, Pimlott SL, Babich JW, Gaze MN, Champion S, Boyd M.

J Nucl Med. 2012 Jul;53(7):1146-54. doi: 10.2967/jnumed.111.095943. Epub 2012 Jun 11.

39.

Molecular imaging of human ACE-1 expression in transgenic rats.

Dilsizian V, Zynda TK, Petrov A, Ohshima S, Tahara N, Haider N, Donohue A, Aras O, Femia FJ, Hillier SM, Joyal JL, Wong ND, Coleman T, Babich JW, Narula J.

JACC Cardiovasc Imaging. 2012 Apr;5(4):409-18. doi: 10.1016/j.jcmg.2011.10.008.

40.

Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents.

Darwish A, Blacker M, Janzen N, Rathmann SM, Czorny S, Hillier SM, Joyal JL, Babich JW, Valliant JF.

ACS Med Chem Lett. 2012 Feb 18;3(4):313-6. doi: 10.1021/ml300003v. eCollection 2012 Apr 12.

41.

123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.

Hillier SM, Kern AM, Maresca KP, Marquis JC, Eckelman WC, Joyal JL, Babich JW.

J Nucl Med. 2011 Jul;52(7):1087-93. doi: 10.2967/jnumed.110.086751. Epub 2011 Jun 16.

42.

Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directions.

Roach M 3rd, Alberini JL, Pecking AP, Testori A, Verrecchia F, Soteldo J, Ganswindt U, Joyal JL, Babich JW, Witte RS, Unger E, Gottlieb R.

J Surg Oncol. 2011 May 1;103(6):587-601. doi: 10.1002/jso.21805. Review.

PMID:
21480253
43.

Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: a multicenter trial.

Kontos MC, Dilsizian V, Weiland F, DePuey G, Mahmarian JJ, Iskandrian AE, Bateman TM, Heller GV, Ananthasubramaniam K, Li Y, Goldman JL, Armor T, Kacena KA, LaFrance ND, Garcia EV, Babich JW, Udelson JE.

J Am Coll Cardiol. 2010 Jul 20;56(4):290-9. doi: 10.1016/j.jacc.2010.03.045.

44.

Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.

Barrett JA, Joyal JL, Hillier SM, Maresca KP, Femia FJ, Kronauge JF, Boyd M, Mairs RJ, Babich JW.

Cancer Biother Radiopharm. 2010 Jun;25(3):299-308. doi: 10.1089/cbr.2009.0695.

45.

Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma.

Joyal JL, Barrett JA, Marquis JC, Chen J, Hillier SM, Maresca KP, Boyd M, Gage K, Nimmagadda S, Kronauge JF, Friebe M, Dinkelborg L, Stubbs JB, Stabin MG, Mairs R, Pomper MG, Babich JW.

Cancer Res. 2010 May 15;70(10):4045-53. doi: 10.1158/0008-5472.CAN-09-4414. Epub 2010 May 4.

46.

Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide.

Maresca KP, Marquis JC, Hillier SM, Lu G, Femia FJ, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.

Bioconjug Chem. 2010 Jun 16;21(6):1032-42. doi: 10.1021/bc900517x.

PMID:
20402463
47.

Synthesis and characterization of rhenium and technetium-99m labeled insulin.

Sundararajan C, Besanger TR, Labiris R, Guenther KJ, Strack T, Garafalo R, Kawabata TT, Finco-Kent D, Zubieta J, Babich JW, Valliant JF.

J Med Chem. 2010 Mar 25;53(6):2612-21. doi: 10.1021/jm100096c.

PMID:
20235598
48.

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW.

Cancer Res. 2009 Sep 1;69(17):6932-40. doi: 10.1158/0008-5472.CAN-09-1682. Epub 2009 Aug 25.

49.

Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.

Coleman RE, Stubbs JB, Barrett JA, de la Guardia M, Lafrance N, Babich JW.

Cancer Biother Radiopharm. 2009 Aug;24(4):469-75. doi: 10.1089/cbr.2008.0584.

PMID:
19694582
50.

Comprehensive radiolabeling, stability, and tissue distribution studies of technetium-99m single amino acid chelates (SAAC).

Maresca KP, Hillier SM, Femia FJ, Zimmerman CN, Levadala MK, Banerjee SR, Hicks J, Sundararajan C, Valliant J, Zubieta J, Eckelman WC, Joyal JL, Babich JW.

Bioconjug Chem. 2009 Aug 19;20(8):1625-33. doi: 10.1021/bc900192b. Epub 2009 Jul 2.

PMID:
19572702

Supplemental Content

Loading ...
Support Center